At Trevena, we are developing innovative therapies to benefit patients and healthcare providers confronting serious medical conditions. Our lead product candidate is oliceridine, a new chemical entity with FDA Breakthrough Therapy designation that has successfully completed three Phase 3 trials for the management of moderate-to-severe acute pain. Oliceridine was specifically designed to improve conventional opioid pharmacology to deliver the pain relief of an opioid but with fewer associated adverse effects. Our history is rooted in strong science – Trevena was founded to translate Nobel Prize-winning research into a new generation of groundbreaking medicines.
Copyright 2016, a2z, Inc. All rights reserved.